Synmosa Biopharma Statistics

Total Valuation

Synmosa Biopharma has a market cap or net worth of TWD 13.99 billion. The enterprise value is 16.05 billion.

Market Cap	13.99B
Enterprise Value	16.05B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	Aug 9, 2024

Share Statistics

Synmosa Biopharma has 420.25 million shares outstanding. The number of shares has increased by 5.55% in one year.

Current Share Class	n/a
Shares Outstanding	420.25M
Shares Change (YoY)	+5.55%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	10.83%
Owned by Institutions (%)	5.76%
Float	328.94M

Valuation Ratios

The trailing PE ratio is 19.49 and the forward PE ratio is 15.08.

PE Ratio	19.49
Forward PE	15.08
PS Ratio	2.60
PB Ratio	1.98
P/TBV Ratio	2.13
P/FCF Ratio	28.50
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.42, with an EV/FCF ratio of 32.68.

EV / Earnings	22.35
EV / Sales	2.99
EV / EBITDA	15.42
EV / EBIT	22.76
EV / FCF	32.68

Financial Position

The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.31.

Current Ratio	2.38
Quick Ratio	1.48
Debt / Equity	0.31
Debt / EBITDA	2.46
Debt / FCF	5.27
Interest Coverage	12.45

Financial Efficiency

Return on equity (ROE) is 6.38% and return on invested capital (ROIC) is 4.26%.

Return on Equity (ROE)	6.38%
Return on Assets (ROA)	3.81%
Return on Capital (ROIC)	4.26%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.46
Inventory Turnover	1.79

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.83% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-5.83%
50-Day Moving Average	35.25
200-Day Moving Average	36.19
Relative Strength Index (RSI)	38.31
Average Volume (20 Days)	637,582

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Synmosa Biopharma had revenue of TWD 5.38 billion and earned 718.07 million in profits. Earnings per share was 1.71.

Revenue	5.38B
Gross Profit	2.31B
Operating Income	717.19M
Pretax Income	696.73M
Net Income	718.07M
EBITDA	1.03B
EBIT	717.19M
Earnings Per Share (EPS)	1.71

Full Income Statement

Balance Sheet

The company has 1.78 billion in cash and 2.59 billion in debt, giving a net cash position of -808.50 million or -1.92 per share.

Cash & Cash Equivalents	1.78B
Total Debt	2.59B
Net Cash	-808.50M
Net Cash Per Share	-1.92
Equity (Book Value)	8.33B
Book Value Per Share	16.85
Working Capital	2.84B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 736.99 million and capital expenditures -245.92 million, giving a free cash flow of 491.07 million.

Operating Cash Flow	736.99M
Capital Expenditures	-245.92M
Free Cash Flow	491.07M
FCF Per Share	1.17

Full Cash Flow Statement

Margins

Gross margin is 42.93%, with operating and profit margins of 13.34% and 13.36%.

Gross Margin	42.93%
Operating Margin	13.34%
Pretax Margin	12.96%
Profit Margin	13.36%
EBITDA Margin	19.12%
EBIT Margin	13.34%
FCF Margin	9.14%

Dividends & Yields

This stock pays an annual dividend of 0.55, which amounts to a dividend yield of 1.64%.

Dividend Per Share	0.55
Dividend Yield	1.64%
Dividend Growth (YoY)	18.41%
Years of Dividend Growth	3
Payout Ratio	31.85%
Buyback Yield	-5.55%
Shareholder Yield	-3.91%
Earnings Yield	5.13%
FCF Yield	3.51%

Dividend Details

Stock Splits

The last stock split was on August 9, 2024. It was a forward split with a ratio of 1.1.

Last Split Date	Aug 9, 2024
Split Type	Forward
Split Ratio	1.1

Scores

Synmosa Biopharma has an Altman Z-Score of 3.37.

Altman Z-Score	3.37
Piotroski F-Score	n/a